Fig. 1From: Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish populationModel structure. Figure notes: BMI: body mass index; FEV1: forced expiratory volume in 1 s; ICER: incremental cost-effectiveness ratio; ICUR: incremental cost-utility ratio; IND/GLY: indacaterol/glycopyrronium; NNT: number needed to treat; QALY: quality-adjusted life-year; SFC: salmeterol/fluticasoneBack to article page